Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine

Migraine Clinical Trial

Official title:

A Prospective, Randomized, Vehicle-Controlled, Double-Blind, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of B244 Delivered as an Intranasal Spray for Preventive Treatment in Subjects With Episodic Migraine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03488563
• Other study ID #: MGB244-001
• Status: Completed
• Phase: Phase 2
• Start date: March 30, 2018
• Est. completion date: July 16, 2019

Study information

• Verified date: September 2022
• Source: AOBiome LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, randomized, vehicle-controlled, double-blind, multi-center study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic migraine.

Description:

This is a Prospective, Randomized, Vehicle-controlled, Double-blind, Multi-center, 3-arm study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic migraine.

At Screening and Baseline, all subjects must experiences 4-14 migraine days per month and 3-14 migraine attacks per month and no more than 14 headache days per month in the 3 months prior to screening.

The total duration of the study will be approximately 16 weeks. Participants will report for a Screening visit and if all inclusion criteria are met, subjects will go through a one month baseline period prior to randomization. Subjects will come in for visits at Day 28 (Week 4), Day 56 (Week8), Day 84 (Week12), and Day 112 (Week 16).

Efficacy will be assessed by change in migraine attacks, days, and hours. Blood and urine samples will be collected for standard safety laboratory testing and the effect of the drug on inflammatory biomarkers. Safety will be monitored throughout the study.

Investigators plan to enroll 303 total subjects. Subjects will be randomized 1:1:1 so that an equal number of subjects will be treated in each arm of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 313
• Est. completion date: July 16, 2019
• Est. primary completion date: June 17, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Males and Females, 18 to 65 years of age.

• In good general health as determined by a thorough medical history and physical examination, and vital signs.

• At least a 1-year history of migraine with or without aura that began before the age of 50 years old and consistent with a diagnosis of migraine with or without aura according to the International Classification of Headache Disorders, 3rd edition, beta version.

• Experiences 4-14 migraine days per month and 3-14 migraine attacks per month and no more than 14 headache days per month (including migraine and non-migraine headache days) in the 3 months prior to screening.

• Experiences 4-14 migraine headache days per month during the baseline period.

• Ability and willingness to abstain from taking medications not allowed by the protocol or administering any foreign substance intranasally.

• Ability and willingness to complete a migraine-history diary from screening to treatment with study drug and a migraine-treatment diary from prevention treatment through the remainder of the follow-up period.

Exclusion Criteria:

• Headache on greater than 14 days/month in any of the three months (90 days) preceding entry into the study.

• Use of acute migraine-specific medications (e.g., ergotamine, triptan) on more than 10 days per month in the previous 3 months and during study.

• Use of intranasal migraine medications during study.

• Use of any intranasally administered over-the-counter product or nasal irrigation (e.g., neti pot) during study.

• Opioids/barbiturates used on more than 4 days per month in the previous 3 months and throughout the duration of the study.

• Use of analgesics (including acetaminophen, nonsteroidal anti-inflammatory drugs [NSAIDs], acetylsalicylic acid, or combination analgesics) for migraine and non-migraine headaches on more than 14 days per month in the - Use of migraine prevention medication within two months prior to study and throughout the duration of the study.

• Botulinum toxin injection within 3 months prior to screening or during study.

• Anti-CGRP monoclonal antibody (e.g., erenumab, fremanezumab, galcanezumab, and eptinezumab) injection or infusion within 4 months prior to screening or during study.

• Small molecule anti-CGRP medications in the 30 days prior to the screening visit.

• Use of systemic antibiotics during study.

• Pregnancy or breast-feeding.

• Female of childbearing potential not using adequate contraceptive measures.

• Inability to give informed consent.

• History of neurological, psychiatric, or any other medical condition that in the opinion of the investigator may compromise the subject's ability to safely participate in the study.

• Subjects with any significant clinical abnormalities which may interfere with study participation.

• Prior use of AO+ Mist.

• Subjects with immunodeficiencies, nasal lesions, nasal polyps, or sinus infections.

• Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit.

• Inability to maintain at least 80% diary compliance during the study from baseline to follow-up.

Related Conditions & MeSH terms

• Migraine
• Migraine Disorders

Intervention

Biological:
• B244
B244 Suspension
• Vehicle
Vehicle Suspension

Locations

Country	Name	City	State
United States	FutureSearch Trials of Neurology and Sleep Lab, L.P.	Austin	Texas
United States	Charlottesville Medical Research	Charlottesville	Virginia
United States	CTI Clinical Research Center	Cincinnati	Ohio
United States	FutureSearch Trials of Dallas, L.P.	Dallas	Texas
United States	Neurostudies Clinical Research	Decatur	Georgia
United States	Texas Center for Drug Development	Houston	Texas
United States	Clinical Neuroscience Solution, Inc	Jacksonville	Florida
United States	Altea Research Institute	Las Vegas	Nevada
United States	Precision Clinical Research	Lauderdale Lakes	Florida
United States	Baptist Health Center for Clinical Research	Little Rock	Arkansas
United States	Collaborative Neuroscience Network, LLC	Long Beach	California
United States	Clinical Neuroscience Solution, Inc	Memphis	Tennessee
United States	BTC of New Bedford	New Bedford	Massachusetts
United States	Coastal Carolina Research Center	North Charleston	South Carolina
United States	Clinical Neuroscience Solution, Inc	Orlando	Florida
United States	CI Trials	Riverside	California
United States	Rochester Clinical Research INC	Rochester	New York
United States	Neurological Research Institute	Santa Monica	California
United States	New England Institute for Neurology and Headache (NEINH)/Medical Practice	Stamford	Connecticut
United States	MedVadis Research	Watertown	Massachusetts
United States	Palm Beach Research	West Palm Beach	Florida
United States	PMG Research of Wilmington	Wilmington	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
AOBiome LLC	Veristat, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Mean Change in Days Where Subject Recorded Migraine Associated Symptoms: Nausea/Vomiting, Photophobia and Sonophobia.	Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine associated symptoms: nausea/vomiting, photophobia and sonophobia.	Baseline to Day 112
Primary	Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0	Safety and tolerability endpoints will consist of all adverse events reporting during the study duration.	Baseline to Day 112
Secondary	Mean Change in Monthly Migraine Days.	Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine days (experiencing migraine with or without aura in a given day).	Baseline to Day 84
Secondary	Mean Change in Monthly Migraine Attacks.	Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine attacks (an episode of any qualified migraine headache. To distinguish an attack of long duration from two attacks or to distinguish between attacks and relapses: A migraine attack that is interrupted by sleep, or temporarily remits, and then recurs within 48 hours (i.e., <48 hours between the start of the migraine attack to the time of the recurrence) will be considered as one attack and not two.; -An attack treated successfully with medication but with relapse within 48 hours (i.e., <48 hours between the start of the migraine attack to the time of recurrence) will be considered as one attack.)	Baseline to Day 84
Secondary	Proportion of Subjects Experiencing a 50%, 75%, and 100% Reduction in Monthly Migraine Days.	Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on migraine days (experiencing migraine with or without aura in a given day).	Baseline to Day 112
Secondary	Mean Change in Monthly Acute Migraine Specific Medication Days.	Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included use of rescue (acute migraine specific) medications and dosing administration.	Baseline to Day 84
Secondary	Mean Change in Monthly Headache Days.	Subjects made daily entries to include recordings of migraine frequency, duration, and severity that included information on headache days (a non-migraine headache day)	Baseline to Day 84
Secondary	Mean Change From Baseline to 12 Weeks of Treatment in Disability, as Measured by the Migraine Disability Assessment (MIDAS)	The Migraine Disability Assessment (MIDAS) questionnaire was administered to study examine the relationship between the impact of migraine and quality of life where subjects scored 5 questions on a scale of 0 to 21+ (0-5=little or no disability, 6-10=mild disability, 11-20=moderate disability, 21+=severe disability). The total score ranges from 0 to 90.	Baseline to Day 84
Secondary	Mean Change From Baseline to 12 Weeks of Treatment in Monthly Headache Impact Test-6 (HIT-6) Questionnaire	The Headache Impact Test-6 (HIT-6) questionnaire was administered to examine the relationship between impact of migraine and quality of life. The total score ranges from 36 to 78 where a higher score indicates a greater impact on quality of life (Class I: 36-49, Class II: 50-55, Class III: 56-59, Class IV: 60+).	Baseline to Day 84
Secondary	Mean Change From Baseline to 12 Weeks of Treatment in Monthly Migraine Specific Quality of Life Questionnaire (MSQL)	The Migraine Specific Quality of Life (MSQL) questionnaire was used to examine the impact of migraine on health-related quality of life across three domains: Role Function-Restrictive (7 questions) examines the degree to which performance of daily activities is limited by migraine; Role Function-Preventive (4 questions) examines the degree to which performance of daily activities is prevented by migraine; Emotional Function (3 questions) examines feelings of frustration and helplessness due to migraine. Total score for each domain ranges from 0 to 100, where a higher score indicates greater severity.	Baseline to Day 84

External Links

•   Related information for potential participants